{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:40:17Z","timestamp":1773873617390,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Johnson and Johnson Innovative Medicine"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s41669-025-00617-8","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T14:53:23Z","timestamp":1769180003000},"page":"341-354","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Content Validity of Two Generic Preference-Based Measures in Retinitis Pigmentosa, Including X-Linked Retinitis Pigmentosa"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6374-5948","authenticated-orcid":false,"given":"Louis S.","family":"Matza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy A.","family":"Howell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaoyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Denee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"617_CR1","unstructured":"Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. 2017:1-76. https:\/\/www.cda-amc.ca\/sites\/default\/files\/pdf\/guidelines_for_the_economic_evaluation_of_health_technologies_canada_4th_ed.pdf. Accessed 15 Apr 2025."},{"key":"617_CR2","unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluations: The manual. London, UK [December 2022]. Available from: https:\/\/www.nice.org.uk\/process\/pmg36\/resources\/nice-health-technology-evaluations-the-manual-pdf-72286779244741. Accessed 15 Apr 2025."},{"key":"617_CR3","unstructured":"Pharmaceutical Benefits Advisory Committee. Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee. Version 5.0. 2016:1-216. https:\/\/pbac.pbs.gov.au\/content\/information\/files\/pbac-guidelines-version-5.pdf. Accessed 15 Apr 2025."},{"key":"617_CR4","unstructured":"Institute for Clinical and Economic Review. ICER\u2019s reference case for economic evaluations: Elements and rationale. 2024:1-47. https:\/\/icer.org\/wp-content\/uploads\/2024\/02\/Reference-Case-4.3.25.pdf. Accessed 15 Apr 2025."},{"issue":"5","key":"617_CR5","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/j.1524-4733.2009.00527.x","volume":"12","author":"C Czoski-Murray","year":"2009","unstructured":"Czoski-Murray C, Carlton J, Brazier J, Young T, et al. Valuing condition-specific health states using simulation contact lenses. Value Health. 2009;12(5):793\u20139.","journal-title":"Value Health"},{"issue":"9","key":"617_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta18090","volume":"18","author":"L Longworth","year":"2014","unstructured":"Longworth L, Yang Y, Young T, Mulhern B, et al. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Health Technol Assess. 2014;18(9):1\u2013224.","journal-title":"Health Technol Assess"},{"issue":"10","key":"617_CR7","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1007\/s11136-013-0412-y","volume":"22","author":"RK Naik","year":"2013","unstructured":"Naik RK, Gries KS, Rentz AM, Kowalski JW, Revicki DA. Psychometric evaluation of the National Eye Institute Visual Function Questionnaire and Visual Function Questionnaire Utility Index in patients with non-infectious intermediate and posterior uveitis. Qual Life Res. 2013;22(10):2801\u20138.","journal-title":"Qual Life Res"},{"issue":"11","key":"617_CR8","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s40273-015-0295-6","volume":"33","author":"N Payakachat","year":"2015","unstructured":"Payakachat N, Ali MM, Tilford JM. Can the EQ-5D detect meaningful change? A systematic review. Pharmacoeconomics. 2015;33(11):1137\u201354.","journal-title":"Pharmacoeconomics"},{"key":"617_CR9","doi-asserted-by":"publisher","first-page":"835","DOI":"10.2147\/OPTH.S300226","volume":"15","author":"K Rojananuangnit","year":"2021","unstructured":"Rojananuangnit K, Sudjinda N. Utility index and patient-reported outcome measures in glaucomatous patients comparing with normal participants. Clin Ophthalmol. 2021;15:835\u201343.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"617_CR10","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jval.2011.08.002","volume":"15","author":"J Tosh","year":"2012","unstructured":"Tosh J, Brazier J, Evans P, Longworth L. A review of generic preference-based measures of health-related quality of life in visual disorders. Value Health. 2012;15(1):118\u201327.","journal-title":"Value Health"},{"issue":"3","key":"617_CR11","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s11136-006-9126-8","volume":"16","author":"N Bansback","year":"2007","unstructured":"Bansback N, Czoski-Murray C, Carlton J, Lewis G, et al. Determinants of health related quality of life and health state utility in patients with age related macular degeneration: the association of contrast sensitivity and visual acuity. Qual Life Res. 2007;16(3):533\u201343.","journal-title":"Qual Life Res"},{"issue":"7","key":"617_CR12","doi-asserted-by":"publisher","first-page":"A571","DOI":"10.1016\/j.jval.2016.09.1297","volume":"19","author":"B Lescrauwaet","year":"2016","unstructured":"Lescrauwaet B, Brazier J, Aly A, Hirnei\u00df C, Patel P. Use of novel health-related quality of life measures to assess the effect of metamorphopsia symptoms in patients with vitreomacular traction, with or without macular hole: the memo study. Value Health. 2016;19(7):A571.","journal-title":"Value Health"},{"issue":"4","key":"617_CR13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1159\/000511591","volume":"64","author":"P Massin","year":"2021","unstructured":"Massin P, Creuzot-Garcher C, Kodjikian L, Girmens JF, et al. Real-world outcomes after 36-month treatment with ranibizumab 0.5 mg in patients with visual impairment due to diabetic macular edema (BOREAL-DME). Ophthalmic Res. 2021;64(4):577\u201386.","journal-title":"Ophthalmic Res"},{"issue":"8","key":"617_CR14","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1017\/S0012162206001381","volume":"48","author":"M Boulton","year":"2006","unstructured":"Boulton M, Haines L, Smyth D, Fielder A. Health-related quality of life of children with vision impairment or blindness. Dev Med Child Neurol. 2006;48(8):656\u201361.","journal-title":"Dev Med Child Neurol"},{"issue":"11","key":"617_CR15","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1001\/archopht.122.11.1659","volume":"122","author":"GE Quinn","year":"2004","unstructured":"Quinn GE, Dobson V, Saigal S, Phelps DL, et al. Health-related quality of life at age 10 years in very low-birth-weight children with and without threshold retinopathy of prematurity. Arch Ophthalmol. 2004;122(11):1659\u201366.","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"617_CR16","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jval.2011.11.031","volume":"15","author":"E Heintz","year":"2012","unstructured":"Heintz E, Wirehn AB, Peebo BB, Rosenqvist U, Levin LA. QALY weights for diabetic retinopathy\u2013a comparison of health state valuations with HUI-3, EQ-5D, EQ-VAS, and TTO. Value Health. 2012;15(3):475\u201384.","journal-title":"Value Health"},{"key":"617_CR17","unstructured":"Food and Drug Administration. Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments. Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. 2025:1-53. https:\/\/www.fda.gov\/media\/159500\/download. Accessed 15 Apr 2025."},{"issue":"8","key":"617_CR18","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, et al. Content validity\u2013establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: Part 2\u2013assessing respondent understanding. Value Health. 2011;14(8):978\u201388.","journal-title":"Value Health"},{"issue":"8","key":"617_CR19","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, et al. Content validity\u2013establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: Part 1\u2013eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967\u201377.","journal-title":"Value Health"},{"key":"617_CR20","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2147\/CEOR.S297287","volume":"13","author":"M Chivers","year":"2021","unstructured":"Chivers M, Li N, Pan F, Wieffer H, et al. The burden of x-linked retinitis pigmentosa on patients and society: A narrative literature review. Clinicoecon Outcomes Res. 2021;13:565\u201372.","journal-title":"Clinicoecon Outcomes Res."},{"issue":"3","key":"617_CR21","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41591-020-0763-1","volume":"26","author":"J Cehajic-Kapetanovic","year":"2020","unstructured":"Cehajic-Kapetanovic J, Xue K, Martinez-Fernandez de la Camara C, Nanda A, et al. Initial results from a first-in-human gene therapy trial on x-linked retinitis pigmentosa caused by mutations in RPGR. Nat Med. 2020;26(3):354\u20139.","journal-title":"Nat Med"},{"key":"617_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2019.100827","volume":"77","author":"AV Garafalo","year":"2020","unstructured":"Garafalo AV, Cideciyan AV, Heon E, Sheplock R, et al. Progress in treating inherited retinal diseases: early subretinal gene therapy clinical trials and candidates for future initiatives. Prog Retin Eye Res. 2020;77:100827.","journal-title":"Prog Retin Eye Res"},{"issue":"3","key":"617_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/21678707.2018.1444476","volume":"6","author":"C Martinez-Fernandez De La Camara","year":"2018","unstructured":"Martinez-Fernandez De La Camara C, Nanda A, Salvetti AP, Fischer MD, MacLaren RE. Gene therapy for the treatment of x-linked retinitis pigmentosa. Expert Opin Orphan Drugs. 2018;6(3):167\u201377.","journal-title":"Expert Opin Orphan Drugs"},{"issue":"7","key":"617_CR24","first-page":"3846","volume":"63","author":"M Michaelides","year":"2022","unstructured":"Michaelides M, Xu J, Wang D, Wong P, et al. AAV5-RPGR (botaretigene sparoparvovec) gene therapy for x-linked retinitis pigmentosa (XLRP) demonstrates localized improvements in static perimetry. Invest Ophthalmol Vis Sci. 2022;63(7):3846\u2013946.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"617_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2021.114523","volume":"292","author":"M Hennink","year":"2022","unstructured":"Hennink M, Kaiser BN. Sample sizes for saturation in qualitative research: a systematic review of empirical tests. Soc Sci Med. 2022;292:114523.","journal-title":"Soc Sci Med"},{"issue":"4","key":"617_CR26","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1177\/1049732316665344","volume":"27","author":"MM Hennink","year":"2017","unstructured":"Hennink MM, Kaiser BN, Marconi VC. Code saturation versus meaning saturation: how many interviews are enough? Qual Health Res. 2017;27(4):591\u2013608.","journal-title":"Qual Health Res"},{"issue":"7","key":"617_CR27","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jval.2017.11.014","volume":"21","author":"DM Turner-Bowker","year":"2018","unstructured":"Turner-Bowker DM, Lamoureux RE, Stokes J, Litcher-Kelly L, et al. Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development. Value Health. 2018;21(7):839\u201342.","journal-title":"Value Health"},{"issue":"3","key":"617_CR28","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group. EuroQol\u2013a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199\u2013208.","journal-title":"Health Policy"},{"key":"617_CR29","first-page":"191","volume-title":"Quality of life and pharmacoeconomics in clinical trials","author":"P Kind","year":"1996","unstructured":"Kind P. The EuroQol instrument: An index of health related quality of life. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia, PA: Lippincott Raven Publishers; 1996. p. 191\u2013201.","edition":"2"},{"issue":"1","key":"617_CR30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jval.2013.10.006","volume":"17","author":"R Rabin","year":"2014","unstructured":"Rabin R, Gudex C, Selai C, Herdman M. From translation to version management: a history and review of methods for the cultural adaptation of the Euroqol Five-Dimensional Questionnaire. Value Health. 2014;17(1):70\u20136.","journal-title":"Value Health"},{"issue":"8","key":"617_CR31","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jval.2019.02.009","volume":"22","author":"AS Pickard","year":"2019","unstructured":"Pickard AS, Law EH, Jiang R, Pullenayegum E, et al. United States valuation of EQ-5D-5L health states using an international protocol. Value Health. 2019;22(8):931\u201341.","journal-title":"Value Health"},{"key":"617_CR32","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/oso\/9780198527695.003.0025","volume-title":"Assessing quality of life in clinical trials","author":"D Feeny","year":"2005","unstructured":"Feeny D. Preference-based measures: Utility and quality-adjusted life years. In: Fayers P, Hays R, editors. Assessing quality of life in clinical trials. 2nd ed. New York: Oxford University Press; 2005. p. 405\u201331.","edition":"2"},{"key":"617_CR33","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1477-7525-1-54","volume":"1","author":"J Horsman","year":"2003","unstructured":"Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes. 2003;1:54.","journal-title":"Health Qual Life Outcomes"},{"issue":"7","key":"617_CR34","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1097\/00005650-199607000-00004","volume":"34","author":"GW Torrance","year":"1996","unstructured":"Torrance GW, Feeny DH, Furlong WJ, Barr RD, et al. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Med Care. 1996;34(7):702\u201322.","journal-title":"Med Care"},{"key":"617_CR35","unstructured":"Furlong WJ, Feeny DH, Torrance GW. Health State Utilities Index (HUI) procedures manual: Algorithm for determining HUI Mark 2 (HUI2)\/Mark 3 (HUI3) health status classification levels, health states, single-attribute level utility scores, and overall health-related quality of life utility scores from 15-item self-complete health status questionnaires (also referred to as HUI123.15Q questionnaires). Dundas, ON: HUInc. 2014; 1-76."},{"issue":"2","key":"617_CR36","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/00005650-200202000-00006","volume":"40","author":"D Feeny","year":"2002","unstructured":"Feeny D, Furlong W, Torrance GW, Goldsmith CH, et al. Multiattribute and single-attribute utility functions for the Health Utilities Index Mark 3 system. Med Care. 2002;40(2):113\u201328.","journal-title":"Med Care"},{"issue":"9","key":"617_CR37","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"HF Hsieh","year":"2005","unstructured":"Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277\u201388.","journal-title":"Qual Health Res"},{"issue":"3","key":"617_CR38","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1167\/iovs.06-0971","volume":"48","author":"MA Sandberg","year":"2007","unstructured":"Sandberg MA, Rosner B, Weigel-DiFranco C, Dryja TP, Berson EL. Disease course of patients with x-linked retinitis pigmentosa due to RPGR gene mutations. Invest Ophthalmol Vis Sci. 2007;48(3):1298\u2013304.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"617_CR39","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1097\/OPX.0000000000000004","volume":"90","author":"M Ang","year":"2013","unstructured":"Ang M, Fenwick E, Wong TY, Lamoureux E, Luo N. Utility of EQ-5D to assess patients undergoing cataract surgery. Optom Vis Sci. 2013;90(8):861\u20136.","journal-title":"Optom Vis Sci"},{"key":"617_CR40","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1471-2415-12-43","volume":"12","author":"FM Bozzani","year":"2012","unstructured":"Bozzani FM, Alavi Y, Jofre-Bonet M, Kuper H. A comparison of the sensitivity of EQ-5D, SF-6D and TTO utility values to changes in vision and perceived visual function in patients with primary open-angle glaucoma. BMC Ophthalmol. 2012;12:43.","journal-title":"BMC Ophthalmol"},{"issue":"8","key":"617_CR41","doi-asserted-by":"publisher","first-page":"e783","DOI":"10.1111\/aos.13430","volume":"95","author":"AF Macedo","year":"2017","unstructured":"Macedo AF, Ramos PL, Hernandez-Moreno L, Cima J, et al. Visual and health outcomes, measured with the activity inventory and the EQ-5D, in visual impairment. Acta Ophthalmol. 2017;95(8):e783\u201391.","journal-title":"Acta Ophthalmol"},{"issue":"11","key":"617_CR42","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1167\/iovs.05-0072","volume":"46","author":"M Espallargues","year":"2005","unstructured":"Espallargues M, Czoski-Murray CJ, Bansback NJ, Carlton J, et al. The impact of age-related macular degeneration on health status utility values. Invest Ophthalmol Vis Sci. 2005;46(11):4016\u201323.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"617_CR43","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1001\/jamaophthalmol.2013.7639","volume":"132","author":"AM Rentz","year":"2014","unstructured":"Rentz AM, Kowalski JW, Walt JG, Hays RD, et al. Development of a preference-based index from the National Eye Institute Visual Function Questionnaire-25. JAMA Ophthalmol. 2014;132(3):310\u20138.","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"617_CR44","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3111\/13696998.2012.670175","volume":"15","author":"P Swinburn","year":"2012","unstructured":"Swinburn P, Wang J, Chandiwana D, Mansoor W, Lloyd A. Elicitation of health state utilities in neuroendocrine tumours. J Med Econ. 2012;15(4):681\u20137.","journal-title":"J Med Econ"},{"issue":"1","key":"617_CR45","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jval.2014.09.004","volume":"18","author":"Y Yang","year":"2015","unstructured":"Yang Y, Rowen D, Brazier J, Tsuchiya A, et al. An exploratory study to test the impact on three \u201cbolt-on\u201d items to the EQ-5D. Value Health. 2015;18(1):52\u201360.","journal-title":"Value Health"},{"issue":"7","key":"617_CR46","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s10198-025-01761-y","volume":"26","author":"LS Matza","year":"2025","unstructured":"Matza LS, Li N, Stewart KS, Hashim M, et al. Health state utilities associated with x-linked retinitis pigmentosa (XLRP). Eur J Health Econ. 2025;26(7):1263\u201373. https:\/\/doi.org\/10.1007\/s10198-025-01761-y.","journal-title":"Eur J Health Econ"},{"issue":"4","key":"617_CR47","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s11136-014-0834-1","volume":"24","author":"D Golicki","year":"2015","unstructured":"Golicki D, Niewada M, Buczek J, Karlinska A, et al. Validity of EQ-5D-5L in stroke. Qual Life Res. 2015;24(4):845\u201350.","journal-title":"Qual Life Res"},{"key":"617_CR48","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.parkreldis.2019.01.014","volume":"62","author":"A Kuspinar","year":"2019","unstructured":"Kuspinar A, Mate K, Lafontaine AL, Mayo N. Evaluating the content validity of generic preference-based measures for use in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2019;62:112\u20136.","journal-title":"Parkinsonism Relat Disord"},{"key":"617_CR49","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12955-015-0373-7","volume":"13","author":"LS Matza","year":"2015","unstructured":"Matza LS, Boye KS, Stewart KD, Curtis BH, et al. A qualitative examination of the content validity of the EQ-5D-5L in patients with type 2 diabetes. Health Qual Life Outcomes. 2015;13:192.","journal-title":"Health Qual Life Outcomes"},{"key":"617_CR50","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2147\/PROM.S313512","volume":"12","author":"N Peters","year":"2021","unstructured":"Peters N, Dal Bello-Haas V, Packham T, Chum M, et al. Do generic preference-based measures accurately capture areas of health-related quality of life important to individuals with amyotrophic lateral sclerosis: A content validation study. Patient Relat Outcome Meas. 2021;12:191\u2013203.","journal-title":"Patient Relat Outcome Meas."},{"issue":"1","key":"617_CR51","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1023\/A:1014406429385","volume":"11","author":"M Silberfeld","year":"2002","unstructured":"Silberfeld M, Rueda S, Krahn M, Naglie G. Content validity for dementia of three generic preference based health related quality of life instruments. Qual Life Res. 2002;11(1):71\u20139.","journal-title":"Qual Life Res"},{"issue":"1","key":"617_CR52","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12955-018-0970-3","volume":"16","author":"D Whalley","year":"2018","unstructured":"Whalley D, Globe G, Crawford R, Doward L, et al. Is the EQ-5D fit for purpose in asthma? Acceptability and content validity from the patient perspective. Health Qual Life Outcomes. 2018;16(1):160.","journal-title":"Health Qual Life Outcomes"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00617-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-025-00617-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00617-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:04:52Z","timestamp":1773846292000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-025-00617-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["617"],"URL":"https:\/\/doi.org\/10.1007\/s41669-025-00617-8","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LM and TH are employed by Thermo Fisher Scientific, a company that received funding from Johnson & Johnson Innovative Medicine for time spent conducting this research. QZ and TD are employed by Johnson & Johnson Innovative Medicine and hold company stocks.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Aggregated data can be shared upon reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"The study protocol was approved by an institutional review board (Salus IRB; Study 23234-01), and the study was conducted per the ethical standards as defined in the 1964 Declaration of Helsinki and its later amendments.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All authors contributed to the study conception and design. Material preparation, data collection, and analysis were directed by Timothy Howell and Louis Matza. The first draft of the manuscript was written by Timothy Howell and Louis Matza. The other authors provided edits and comments on the manuscript drafts. All authors read and approved the final manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"All participants signed a form indicating informed consent to participate.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The consent form signed by participants included consent for the results of the study to be published.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}